Journals / Selçuk Tıp Dergisi / 2020 / Cilt: 36 - Sayı: 3

SARS-Cov-2 Immunopathogenesis and Possible Anti-Inflammatory Treatment Options

SARS-Cov-2 İmmunopatogenezi ve Olası Anti-İnflamatuvar Tedavi Seçenekleri

Pages
264–273
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, the immunopathogenesis of SARS-CoV-2 and the treatment models that can be effective on immunopathogenesis are reviewed in the light of current literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Towards the end of 2019, new coronavirus causing acute respiratory distress syndrome in patients was detected in Wuhan Province, China .
📊
Key Findings & Data:This virus was called serious acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Virus Taxonomy Committee.
💡
Conclusion & Impact:In this article, the immunopathogenesis of SARS-CoV-2 and the treatment models that can be effective on immunopathogenesis are reviewed in the light of current literature.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Towards the end of 2019, new coronavirus causing acute respiratory distress syndrome in patients was detected in Wuhan Province, China . This virus was called serious acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Virus Taxonomy Committee. The disease caused by this new coronavirus was called coronavirus disease-2019 (COVID-19) by the World Health Organization. This virus was found to be in the subclass of Betakoronavirus caused by bats. The role of viral proteins such as envelopes, membranes, nucleocapsids and spike proteins responsible for viral infectivity in immunopathogenesis is being investigated in studies. It has been emphasized in studies in which multiple organ failure develops due to the development of cytokine storm, especially in the advanced stages of the disease. An effective host immune response, including natural and adaptive immunity to SARS-Cov-2, is essential for controlling and treating viral infection. Although there is no effective treatment for the disease today, the benefits of various immunosuppressive and immunomodulatory drugs have been shown in studies. In this article, the immunopathogenesis of SARS-CoV-2 and the treatment models that can be effective on immunopathogenesis are reviewed in the light of current literature.

Özet

2019'un sonlarına doğru, Çin'in Wuhan Eyaletinde hastalarda akut solunum sıkıntısı sendromuna neden olan yeni koronavirüs tespit edildi. Bu virüse, Uluslararası Virüs Taksonomi Komitesi tarafından ciddi akut solunum sendromu koronavirüs 2 (SARS-CoV-2) adı verildi. Bu yeni koronavirüsün neden olduğu hastalığa ise Dünya Sağlık Örgütü tarafından koronavirüs hastalığı-2019 (COVID-19) adı verildi. Bu virüsün yarasalardan kaynaklanan Betakoronavirus alt sınıfında olduğu belirlenmiştir. Viral enfektiviteden sorumlu zarf, membran, nükleokapsid ve spike proteinleri gibi viral proteinlerin immünopatogenezdeki rolü çalışmalarda araştırılmaktadır. Özellikle hastalığın ileri evrelerinde sitokin fırtınası gelişimine bağlı çoklu organ yetmezliklerinin geliştiği çalışmalarda vurgulanmıştır. SARS-CoV-2'ye karşı doğal ve adaptif bağışıklık da dahil olmak üzere etkin konakçı bağışıklık yanıtı viral enfeksiyonu kontrol etmek ve tedavi için çok önemlidir. Günümüzde hastalıkta etkili bir tedavi bulunamamakla beraber çalışmalarda çeşitli immünsupresif ve immunmodülatör özelliği olan bazı ilaçların faydası gösterilmiştir. Bu yazıda SARS-CoV-2’nin immunopatogezi ve bunun üzerinden etkili olabilecek tedavi modelleri, güncel literatür eşliğinde gözden geçirilmiştir.

🔖

Cite This Article

ATAY, Ö., ASİLSOY, S. (2020). SARS-Cov-2 Immunopathogenesis and Possible Anti-Inflammatory Treatment Options. Selçuk Tıp Dergisi, Cilt: 36 - Sayı: 3, 264–273. https://ajindex.com/articles/319009

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579(7798):270-3.
  2. Gorbalenya AG, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536-44. Novel Coronavirus (2019-nCoV) Situation Report – 22, World Health Organization 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situationreports/20200211-sitrep-22-ncov.pdf
  3. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine 2020;8(4):420-2.
  4. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China. Jama 2020;323(11):1061-9.
  5. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine 2020;382(18):1708-20.
  6. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018;23(2):130-7.
  7. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. The Lancet 2020;395(10224):565-74.
  8. Ziebuhr J, Snijder EJ, Gorbalenya AE. Virus-encoded proteinases and proteolytic processing in the Nidovirales. The Journal of General Virology 2000;81(4):853-79.
  9. Baez-Santos YM, St John SE, Mesecar AD. The SARScoronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral Research 2015;115:21-38.
  10. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. Journal of Medical Virology 2020;92(4):424-32.
  11. Lu X, Pan J, Tao J, et al. SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes 2011;42(1):37-45. Masters PS. The molecular biology of coronaviruses. Advances in Virus Research 2006;66:193-292.
  12. Ujike M, Taguchi F. Incorporation of spike and membrane glycoproteins into coronavirus virions. Viruses 2015;7(4):1700-25.
  13. Neuman BW, Kiss G, Kunding AH, et al. A structural analysis of M protein in coronavirus assembly and morphology. Journal of Structural Biology 2011;174(1):11-22.
  14. Schoeman D, Fielding BC. Coronavirus envelope protein: Current knowledge. Virology Journal 2019;16(1):69. Nieto-Torres JL,